ArticleJournal of health economics and outcomes research2026

Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy.

Alexander Spira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.